Table 5.

An overview of previous studies on the relationship between SV/NSV and phenotype in LVNC patients

Study	Study population	Genetic testing	Prevalence	Relationship with phenotype
Sarcomere variants
Probst et al., 2011	63 European probands (adults and children)	8 genes	18/63 (29%) with mutated MYH7, MYBPC3, ACTC1, TNNT2, or TPM1	No significant differences in average age, cardiac function, and heart failure or tachyarrhythmias at baseline or follow‐up between carriers and noncarriers
Tian et al., 2015	57 Chinese probands (adults and children)	10 genes	7/57 (12%) with mutated MYH7, ACTC1, TNNT2, or TPM1	No significant differences in clinical characteristics at baseline and mortality during follow‐up between carriers and noncarriers
van Waning et al., 2018	327 European probands (adults and children)	45 genes	85/327 (26%) with mutated MYH7, MYBPC3, TTN, ACTC1, ACTN2, TNNC1, TNNT2, MYL2, or TPM1	No significant differences in adverse events at baseline or follow‐up between carriers and noncarriers
Nonsarcomere variants
van Waning et al., 2018	327 European probands (adults and children)	45 genes	19/327 (6%) with mutated DES, DSP, FKTN, HCN4, KCNQ1, LAMP2, LMNA, MIB1, NOTCH1, PLN, RYR2, SCN5A, or TAZ	No significant differences in adverse events at baseline or follow‐up between carriers and noncarriers